Dare Bioscience Inc
NASDAQ:DARE

Watchlist Manager
Dare Bioscience Inc Logo
Dare Bioscience Inc
NASDAQ:DARE
Watchlist
Price: 1.99 USD 2.05% Market Closed
Market Cap: 28.4m USD

Dare Bioscience Inc
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Dare Bioscience Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Dare Bioscience Inc
NASDAQ:DARE
Cash from Operating Activities
-$6.1m
CAGR 3-Years
35%
CAGR 5-Years
21%
CAGR 10-Years
15%
Johnson & Johnson
NYSE:JNJ
Cash from Operating Activities
$24.2B
CAGR 3-Years
4%
CAGR 5-Years
2%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Cash from Operating Activities
$16.6B
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
25%
Pfizer Inc
NYSE:PFE
Cash from Operating Activities
$13.1B
CAGR 3-Years
-21%
CAGR 5-Years
1%
CAGR 10-Years
-1%
Merck & Co Inc
NYSE:MRK
Cash from Operating Activities
$17.1B
CAGR 3-Years
-5%
CAGR 5-Years
9%
CAGR 10-Years
9%
Eli Lilly and Co
NYSE:LLY
Cash from Operating Activities
$16.1B
CAGR 3-Years
26%
CAGR 5-Years
19%
CAGR 10-Years
17%
No Stocks Found

Dare Bioscience Inc
Glance View

Market Cap
27.7m USD
Industry
Pharmaceuticals

Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. The company is headquartered in San Diego, California and currently employs 20 full-time employees. The company went IPO on 2014-04-10. The firm is focused on advancing products for women's health. The company offers a portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health. Its first product, XACIATO, is a vaginal gel used for the treatment of bacterial vaginosis in females having 12 years of age and older. Its pipeline includes various other clinical-stage programs, such as Ovaprene, Sildenafil Cream, 3.6%, DARE-HRT1, DARE-VVA1, DARE-FRT1, and DARE-PTB1. Its pre-clinical-stage programs include DARE-LARC1, DARE-RH1, ADARE-204, and ADARE-214. Ovaprene, is an investigational hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a proprietary cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder.

DARE Intrinsic Value
9.88 USD
Undervaluation 80%
Intrinsic Value
Price

See Also

What is Dare Bioscience Inc's Cash from Operating Activities?
Cash from Operating Activities
-6.1m USD

Based on the financial report for Sep 30, 2025, Dare Bioscience Inc's Cash from Operating Activities amounts to -6.1m USD.

What is Dare Bioscience Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
15%

Over the last year, the Cash from Operating Activities growth was 24%. The average annual Cash from Operating Activities growth rates for Dare Bioscience Inc have been 35% over the past three years , 21% over the past five years , and 15% over the past ten years .

Back to Top